Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Fractyl Health, Inc. ( (GUTS) ).
On September 26, 2025, Fractyl Health announced the 3-month interim results from its REMAIN-1 Midpoint Cohort study, which evaluates the Revita DMR System’s potential to maintain weight loss after GLP-1 drug discontinuation. The study showed that Revita-treated patients lost an additional 2.5% total body weight after stopping tirzepatide, while sham patients regained 10%, indicating strong statistical significance. These findings suggest Revita could be a first-in-class treatment for post-GLP-1 weight maintenance, offering a new therapeutic category in obesity care. The study’s positive results bolster confidence in the ongoing Pivotal Cohort study, which is expected to complete randomization in early 2026, with further data and potential PMA filing anticipated later that year.
The most recent analyst rating on (GUTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
Fractyl Health’s overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and negative cash flows. While recent corporate events and earnings call insights provide some optimism, the company’s financial instability and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Fractyl Health, Inc. is a metabolic therapeutics company focused on pioneering new approaches to treat metabolic diseases, including obesity and type 2 diabetes. The company aims to transform treatment from chronic symptomatic management to durable disease-modifying therapies targeting the root causes of these diseases. Fractyl is based in Burlington, MA, and its lead product candidate, Revita, is designed to remodel the duodenal lining to reverse damage caused by chronic high-fat and high-sugar diets.
Average Trading Volume: 886,884
Technical Sentiment Signal: Sell
Current Market Cap: $71.29M
For an in-depth examination of GUTS stock, go to TipRanks’ Overview page.